Neuronal hyperexcitability represents a critical pathological hallmark in neurodegenerative diseases, characterized by abnormally elevated neuronal firing rates, disrupted excitation-inhibition balance, and increased susceptibility to depolarization events. This mechanism has emerged as a key contributor to disease progression in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia.
Neuronal hyperexcitability is a pathological state characterized by abnormally elevated neuronal firing rates, increased susceptibility to depolarization, and disrupted excitation-inhibition balance. This phenomenon has emerged as a key feature in multiple neurodegenerative diseases, often preceding overt neuronal loss and contributing to disease progression [1]. [2]
The concept of hyperexcitability originated from epilepsy research but has since been recognized as relevant to numerous neurological disorders. In Alzheimer's disease, network hyperexcitability manifests as epileptiform activity, seizures, and altered neural oscillations that correlate with cognitive decline [3]. Similarly, in Parkinson's disease, basal ganglia hyperexcitability contributes to motor symptoms and may influence disease progression [4]. [5]
Neuronal hyperexcitability manifests at multiple levels of neural circuitry. At the single-neuron level, hyperexcitability presents as: [6]
These changes result from complex interactions between intrinsic membrane properties and synaptic inputs. The balance between excitatory glutamatergic and inhibitory GABAergic signaling is critically disrupted, favoring net excitation [7].
Resting membrane potential depolarization is a hallmark of hyperexcitability. Several factors contribute: [8]
Input resistance changes also contribute to hyperexcitability. Decreased input resistance, as occurs with neuronal shrinkage, requires less current to depolarize neurons, effectively increasing excitability. Conversely, increased input resistance, as seen with dendritic atrophy, can also promote hyperexcitability by enhancing synaptic efficacy [9].
Homeostatic plasticity mechanisms normally maintain stable neuronal function but become maladaptive in neurodegenerative contexts: [10]
These mechanisms create a precarious equilibrium that can tip toward hyperexcitability with additional pathological insults [11].
Voltage-gated sodium channel (Nav) dysfunction represents a fundamental mechanism underlying neuronal hyperexcitability. Alterations in sodium channel expression, localization, and function can lead to: [12]
Nav1.1, Nav1.2, and Nav1.6 isoforms have been particularly implicated in neurodegenerative disease contexts. In AD, reduced Nav1.1 expression in inhibitory interneurons contributes to disinhibition and network hyperexcitability [13].
Voltage-gated potassium channels (Kv) play crucial roles in membrane repolarization and firing rate regulation. Loss of potassium channel function: [14]
K+ channel mutations have been linked to episodic ataxia and other excitability disorders. In AD, alterations in Kv1.1 and Kv1.3 channels have been documented, contributing to neuronal dysfunction. [15]
Voltage-gated calcium channels (VGCCs) regulate calcium influx critical for neurotransmitter release, gene expression, and neuronal survival. Dysregulation leads to: [16]
L-type, N-type, and T-type calcium channels have all been implicated in hyperexcitability mechanisms. T-type calcium channel dysfunction is particularly relevant to absence seizures and thalamocortical dysrhythmia [17].
HCN channels play critical roles in regulating neuronal excitability and pacemaker activity. These channels: [18]
HCN channel dysfunction has been implicated in epilepsy and neurodegenerative diseases. Altered HCN channel expression and function contribute to hyperexcitability in both cortical and hippocampal neurons.
Excessive glutamate signaling represents a central mechanism linking hyperexcitability to neurodegeneration. Key processes include:
Glutamate excitotoxicity leads to calcium influx, oxidative stress, mitochondrial dysfunction, and ultimately neuronal death [19]. The amyloid-β-glutamate receptor interaction has been extensively studied as a mechanism linking amyloid pathology to excitotoxic cell death [20].
Loss of inhibitory tone is a hallmark of hyperexcitability in neurodegenerative diseases:
In AD, GABAergic interneurons, particularly parvalbumin-positive and somatostatin-positive populations, show early vulnerability that contributes to network disinhibition [21].
Concomitant with reduced inhibition, excitatory signaling is often enhanced:
Ion channel mutations (channelopathies) provide direct evidence for hyperexcitability mechanisms:
These genetic studies reveal that even subtle alterations in ion channel function can produce dramatic hyperexcitability phenotypes.
Polymorphisms in ion channel and neurotransmission genes modify susceptibility to hyperexcitability in neurodegenerative diseases:
Subclinical epileptiform activity occurs in 10-22% of AD patients, significantly higher than age-matched controls [22]. This activity includes:
Clinical seizures, typically of focal onset, occur in approximately 1-2% of AD patients but may be underdiagnosed due to subtle manifestations.
Quantitative EEG analysis reveals characteristic changes in AD [2:1]:
These abnormalities often precede overt cognitive decline and may serve as early biomarkers [5:1].
Emerging evidence suggests bidirectional relationship between hyperexcitability and tau pathology [6:1]:
This creates a vicious cycle where network hyperactivity accelerates tau spread, which in turn promotes further hyperexcitability.
Network hyperexcitability in AD manifests as:
Basal ganglia hyperexcitability in PD includes:
Motor neuron hyperexcitability in ALS presents as [9:1]:
Developing effective treatments for neuronal hyperexcitability presents significant challenges:
The ideal treatment would normalize hyperexcitability while preserving essential neural functions. This requires precise targeting of specific cellular populations and pathological mechanisms [15:1].
Neuromodulation techniques offer alternative strategies:
These approaches offer promise for personalized treatment of hyperexcitability disorders.
Electroencephalography serves as the primary tool for detecting hyperexcitability-related abnormalities [2:2]:
Neuronal hyperexcitability and neuroinflammation form a vicious cycle in neurodegenerative diseases. Activated microglia release pro-inflammatory cytokines—IL-1β, IL-6, and TNF-α—that directly modulate neuronal ion channel function and synaptic plasticity [11:1]. These inflammatory mediators:
Conversely, hyperexcitable neurons release damage-associated molecular patterns (DAMPs) that further activate microglia, perpetuating the inflammatory response.
Transgenic animal models have provided crucial insights into hyperexcitability mechanisms:
These models allow investigation of disease mechanisms and therapeutic interventions.
Pharmacological manipulation induces hyperexcitability:
These acute models complement genetic models in understanding hyperexcitability.
Diurnal variations in neuronal excitability are increasingly recognized:
Understanding circadian modulation may yield novel therapeutic strategies [18:1].
Key areas for future investigation include:
Palop, J. J., & Mucke, L. Epilepsy and hyperexcitability in Alzheimer's disease. Nature Reviews Neurology. 2010. ↩︎
Babiloni, C., et al. Resting-state EEG and Alzheimer's disease: A review. Clinical Neurophysiology. 2020. ↩︎ ↩︎ ↩︎
Vossel, K. A., et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurology. 2013. ↩︎
Schuepbach, W. M., et al. Neurostimulation for Parkinson's disease with early motor complications. New England Journal of Medicine. 2013. ↩︎
Musaeus, C. S., et al. EEG as a biomarker in Alzheimer's disease and MCI. Journal of Alzheimer's Disease. 2019. ↩︎ ↩︎
Wu, J. W., et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nature Neuroscience. 2016. ↩︎ ↩︎
Palop, J. J., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2011. ↩︎
Brown, P. Oscillatory nature of human basal ganglia activity: Experimental and clinical evidence. Progress in Neurobiology. 2003. ↩︎
Ziemann, U., et al. Cortical hyperexcitability in ALS. Neurology. 2013. ↩︎ ↩︎
Niedermeyer, E., & Lopes da Silva, F. H. Electroencephalography: Basic Principles, Clinical Applications, and Related Fields. Lippincott Williams & Wilkins. 2005. ↩︎
Streit, W. J., et al. The role of microglia in neurodegeneration. Neurobiology of Disease. 2019. ↩︎ ↩︎
Benarroch, E. E. HCN channels: Function and clinical implications. Neurology. 2018. ↩︎
Catterall, W. A., et al. Ion channel diseases. Cold Spring Harbor Perspectives in Biology. 2012. ↩︎
Rogawski, M. A., & Löscher, W. The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience. 2004. ↩︎
Chen, R., et al. Neuromodulation for neurodegenerative disorders. Nature Reviews Neurology. 2021. ↩︎ ↩︎
Minkeviciene, R., et al. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. Journal of Neuroscience. 2009. ↩︎
Treves, S., et al. Chemical models of epilepsy. Neurobiology of Disease. 2020. ↩︎
Bronsard, G., & Amzica, F. Circadian modulation of neuronal excitability. Nature Reviews Neurology. 2022. ↩︎ ↩︎
Lipton, S. A., & Rosenberg, P. A. Excitatory amino acids as a final common pathway for neurologic disorders. New England Journal of Medicine. 1994. ↩︎
Mucke, L., & Selkoe, D. J. Neurotoxicity of amyloid β-protein: Synaptic and network dysfunction. Cold Spring Harbor Perspectives in Medicine. 2012. ↩︎
Verret, L., et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012. ↩︎
Horvath, A. A., et al. Cryptogenic epileptic seizures in Alzheimer disease: A case series. Seizure. 2018. ↩︎